VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...

Prednisolone Acetate Ophthalmic Suspension USP, 1% is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.